Related references
Note: Only part of the references are listed.Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat
Indu Poornima et al.
CIRCULATION-HEART FAILURE (2008)
Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects
Haiqinq Dai et al.
DIABETES OBESITY & METABOLISM (2008)
The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance
T. Nystroem
HORMONE AND METABOLIC RESEARCH (2008)
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
Dean T. Eurich et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
George G. Sokos et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure
Helena Tuunanen et al.
CIRCULATION (2006)
Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure
H. Norrelund et al.
JOURNAL OF INTERNAL MEDICINE (2006)
Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: A new tool for heart failure evaluation
P Agostoni et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium
H Wiggers et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Myocardial substrate metabolism in the normal and failing heart
WC Stanley et al.
PHYSIOLOGICAL REVIEWS (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Insulin-treated dia betes is associated with a marked increase in mortality in patients with advanced heart failure
S Smooke et al.
AMERICAN HEART JOURNAL (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure
H Bentzen et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes
MA Luque et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure
N Suskin et al.
EUROPEAN HEART JOURNAL (2000)
Share Paper
